FDA Rejects Teva's Specifications For Approving Generic Copaxone
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency denies Teva's citizen petition to block approval of pending ANDAs; FDA's Janet Woodcock indicates what tests might be required to show a generic has the same active ingredient as Copaxone.
You may also be interested in...
The Lovenox Benchmark: Copaxone "Far More Complex," Teva Argues In Anti-Generic Petition
Teva is using FDA’s rationale for approving generic Lovenox to argue against the approval of ANDAs for generic versions of its multiple sclerosis drug Copaxone (glatiramer).
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.